Fate Therapeutics Inc

FATENASDAQ NMS - GLOBAL MARKET

Health CareBiotechnology

$2.84

+0.2100 (+7.98%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $0.9100Current: $2.8452-Week High: $2.88

Key Statistics

Open

$2.68

Day High

$2.88

Day Low

$2.64

Prev. Close

$2.63

Volume

5.14M

Avg. Volume

—

Market Cap

$331.03M

P/E (TTM)

-2.61

Forward P/E

—

P/B Ratio

—

52W High

$2.88

52W Low

$0.9100

50D MA

$1.61

200D MA

$1.28

Dividend Yield

—

Beta

—

Performance

+35.2%

+129.0%

+167.9%

YTD

+187.9%

+118.5%

About

William H. Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences (NASDAQ), of Fate Therapeutics (NASDAQ), and of Daré Bioscience, Inc. (NASDAQ) in San Diego, California. He also serves on the board of Iambic Therapeutics (private). He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017–2018). Rastetter also served as a director of Regulus Therapeutics (2013-2025) through its acquisition by Norvartis. He was a partner in the venture firm Venrock (2006–2013), and a trustee at Caltech (2015–2018). He has served as a director (1998–2016) and as chair of Illumina (2005–2016). He advised SVB Leerink (2014–2019) and currently advises Illumina Ventures.

fatetherapeutics.com/